CTX130

BIOLOGICAL2 trials

Sponsors

CRISPR Therapeutics AG

Conditions

Renal Cell CarcinomaT Cell Lymphoma

Phase 1

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

TerminatedNCT04438083

CRISPR Therapeutics AGRenal Cell Carcinoma

Start: 2020-06-16End: 2024-10-08Updated: 2025-01-08

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

TerminatedNCT04502446

CRISPR Therapeutics AGT Cell Lymphoma

Start: 2020-07-31End: 2024-08-30Updated: 2025-01-08

Related Papers

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.

2024-11-2955 citations

Abstract ND02: CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors

Cancer Research2023-05-2912 citations

558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

Regular and Young Investigator Award Abstracts2022-11-0128 citations

S262: THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T-CELL MALIGNANCIES

HemaSphere2022-06-0142 citations